What You Should Know:
– ConcertAI and NeoGenomics (NASDAQ: NEO) announce a joint software-as-a-service solution in hematological malignancies for research analytics, clinical trial design, and clinical trial operational optimization.
– CTO-H provides a research data solution that is unprecedented in its scale, longitudinality and biomarker depth. CTO-H is a major outcome of the collaboration jointly announced on Jan. 8, 2024, and the more recent joint research completed and scheduled for presentation at the 2024 American Society of Hematology Meeting on Monday, Dec. 9, in San Diego.
NeoGenomics and ConcertAI Introduce CTO-H: Transforming Hematological Malignancy Research
In 2023, NeoGenomics and ConcertAI collaborated to redefine research solutions for healthcare providers and biopharmaceutical companies addressing the rising number of new therapeutic entities targeting hematological malignancies. Their efforts culminated in the creation of CTO-H, a robust database comprising:
- Over 370,000 patient lives with detailed clinical attributes.
- 7 to 11 years of patient journey surveillance data.
- Comprehensive biomarker insights, ranging from routine tests to advanced genetic variants.
Believed to be the largest reference dataset for hematological malignancies, CTO-H addresses critical challenges in hematological research. These include:
- Defining representative populations for early-phase clinical trials.
- Ensuring control groups align with the evolving treatment paradigms.
- Navigating complexities in late-phase trials, including competing studies and recruitment within the targeted timeframe.
The treatment landscape for hematological malignancies has evolved significantly over the last five years, offering more effective options for patients. However, this progress has introduced challenges in clinical research, including heterogeneity in standard care, prolonged treatment durations, and increasingly complex measures of response and residual disease.
“CTO-H represents a pivotal achievement in advancing clinical analysis, study design, and execution planning for hematological malignancies,” said Jeff Elton, PhD, founding CEO of ConcertAI. “Its multi-modal solution delivers unparalleled depth in addressing the complexities of this research domain.”
Under this collaboration:
- ConcertAI will deploy CTO-H through its CARAai™ cloud as a SaaS solution.
- NeoGenomics will provide biomarker interpretation, specialized testing services, and expert clinical support to ensure high-confidence analyses and study designs.
Currently available as a pre-release solution, CTO-H will become widely available on January 17, 2025, promising to elevate the precision and efficiency of hematological research.
